MedTrace Logo

Alpha-1 Blockade for Alcohol Use Disorder (AUD)

NCT04135846 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 184

Last updated 2026-03-20

No results posted yet for this study

Summary

The goal of this research is to replicate findings previously conducted in a pilot trial and to understand, mechanistically, the role of stress in the development of AUD pharmacotherapies that target noradrenergic blockade.

Conditions

  • Alcohol Use Disorder (AUD)

Interventions

DRUG

Doxazosin

16 mg or maximum tolerated dose (MTD)

DRUG

Placebo

Matching placebo

Sponsors & Collaborators

  • Brown University

    lead OTHER

Principal Investigators

  • Carolina L Haass-Koffler, PHARMD, PHD · Brown University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-19
Primary Completion
2026-08-31
Completion
2026-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04135846 on ClinicalTrials.gov